These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 19879961

  • 1. Thyroid hormone and angiogenesis.
    Luidens MK, Mousa SA, Davis FB, Lin HY, Davis PJ.
    Vascul Pharmacol; 2010; 52(3-4):142-5. PubMed ID: 19879961
    [Abstract] [Full Text] [Related]

  • 2. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ.
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of nongenomic actions of thyroid hormone.
    Davis PJ, Leonard JL, Davis FB.
    Front Neuroendocrinol; 2008 May; 29(2):211-8. PubMed ID: 17983645
    [Abstract] [Full Text] [Related]

  • 4. Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA).
    Mousa SS, Davis FB, Davis PJ, Mousa SA.
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):288-93. PubMed ID: 19903697
    [Abstract] [Full Text] [Related]

  • 5. Identification and functions of the plasma membrane receptor for thyroid hormone analogues.
    Lin HY, Cody V, Davis FB, Hercbergs AA, Luidens MK, Mousa SA, Davis PJ.
    Discov Med; 2011 Apr; 11(59):337-47. PubMed ID: 21524387
    [Abstract] [Full Text] [Related]

  • 6. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.
    Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ.
    Circ Res; 2004 Jun 11; 94(11):1500-6. PubMed ID: 15117822
    [Abstract] [Full Text] [Related]

  • 7. Thyroid Hormone, Hormone Analogs, and Angiogenesis.
    Davis PJ, Sudha T, Lin HY, Mousa SA.
    Compr Physiol; 2015 Dec 15; 6(1):353-62. PubMed ID: 26756636
    [Abstract] [Full Text] [Related]

  • 8. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model.
    Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X.
    Int Angiol; 2006 Dec 15; 25(4):407-13. PubMed ID: 17164749
    [Abstract] [Full Text] [Related]

  • 9. Thyroid hormone as a regulator of tumor induced angiogenesis.
    Pinto M, Soares P, Ribatti D.
    Cancer Lett; 2011 Feb 28; 301(2):119-26. PubMed ID: 21183275
    [Abstract] [Full Text] [Related]

  • 10. Thyroid hormone induced angiogenesis through the integrin αvβ3/protein kinase D/histone deacetylase 5 signaling pathway.
    Liu X, Zheng N, Shi YN, Yuan J, Li L.
    J Mol Endocrinol; 2014 Jun 28; 52(3):245-54. PubMed ID: 24532656
    [Abstract] [Full Text] [Related]

  • 11. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
    Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA.
    Anticancer Res; 2009 Oct 28; 29(10):3825-31. PubMed ID: 19846915
    [Abstract] [Full Text] [Related]

  • 12. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications.
    Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY.
    Annu Rev Pharmacol Toxicol; 2011 Oct 28; 51():99-115. PubMed ID: 20868274
    [Abstract] [Full Text] [Related]

  • 13. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated.
    Mousa SA, O'Connor L, Davis FB, Davis PJ.
    Endocrinology; 2006 Apr 28; 147(4):1602-7. PubMed ID: 16384862
    [Abstract] [Full Text] [Related]

  • 14. Thyroid hormone targets matrix Gla protein gene associated with vascular smooth muscle calcification.
    Sato Y, Nakamura R, Satoh M, Fujishita K, Mori S, Ishida S, Yamaguchi T, Inoue K, Nagao T, Ohno Y.
    Circ Res; 2005 Sep 16; 97(6):550-7. PubMed ID: 16100044
    [Abstract] [Full Text] [Related]

  • 15. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor.
    Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK.
    Am J Physiol Endocrinol Metab; 2009 Dec 16; 297(6):E1238-46. PubMed ID: 19755667
    [Abstract] [Full Text] [Related]

  • 16. Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells.
    Davis PJ, Zhou M, Davis FB, Lansing L, Mousa SA, Lin HY.
    Physiol Behav; 2010 Feb 09; 99(2):237-9. PubMed ID: 19248795
    [Abstract] [Full Text] [Related]

  • 17. Tetrac as an anti-angiogenic agent in cancer.
    Schmohl KA, Nelson PJ, Spitzweg C.
    Endocr Relat Cancer; 2019 Jun 01; 26(6):R287-R304. PubMed ID: 31063970
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.
    J Pharmacol Exp Ther; 2001 Dec 01; 299(3):1073-85. PubMed ID: 11714897
    [Abstract] [Full Text] [Related]

  • 19. Nongenomic Actions of Thyroid Hormone: The Integrin Component.
    Davis PJ, Mousa SA, Lin HY.
    Physiol Rev; 2021 Jan 01; 101(1):319-352. PubMed ID: 32584192
    [Abstract] [Full Text] [Related]

  • 20. Promotion by thyroid hormone of cytoplasm-to-nucleus shuttling of thyroid hormone receptors.
    Davis PJ, Davis FB, Lin HY.
    Steroids; 2008 Oct 01; 73(9-10):1013-7. PubMed ID: 18329679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.